Beximco Pharmaceuticals Ltd Notification of Preliminary Results and AGM (7172Q)

TIDMBXP

RNS Number : 7172Q

Beximco Pharmaceuticals Ltd

20 October 2023

20 October 2023

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS LIMITED

Notification of Preliminary Results and Annual General Meeting

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 19 October 2023. Please see further detail as follows:

 
1.  To recommend the approval     The Audited Financial Statements 
     of the Financial Statements   for the year ended 30 June 2023 
     for the year ended 30         have been approved. The full accounts 
     June 2023                     are expected to be announced by 
                                   01 November 2023 
2.  Date & Time of 47 (th)        28 December 2023 at 10.30 A.M. 
     Annual General Meeting 
     ("AGM") of the Company 
     for the year ended 30 
     June, 2023 
3.  Venue of AGM                  Virtual Platform 
4.  Proposed Dividend for         35% Cash Dividend (i.e. Tk 3.50 
     the year ended 30 June        per Share) 
     2023 
5.  Record date                   13 November 2023 
 

Comparative Financial Disclosures:

Beximco Pharmaceuticals Limited (Stand-alone)

 
Particulars                                Year ended          Year ended 
                                         30 June 2023        30 June 2022 
Net Profit after Tax                Tk. 4,588,008,908   Tk. 5,161,343,643 
Earnings Per Share (EPS)                    Tk. 10.28           Tk. 11.57 
Net Asset Value (NAV)              Tk. 43,341,239,142  Tk. 40,315,738,301 
Net Asset Value per share (NAVPS)           Tk. 97.15           Tk. 90.37 
Net Operating Cash Flow Per Share           Tk. 12.96           Tk. 11.27 
 (NOCFPS) 
 

Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)

 
Particulars                                Year ended          Year ended 
                                         30 June 2023        30 June 2022 
Net Profit after Tax                Tk. 4,524,468,490   Tk. 4,998,628,197 
Earnings Per Share (EPS)                    Tk. 10.34           Tk. 11.48 
Net Asset Value (NAV)              Tk. 43,680,703,738  Tk. 40,600,497,817 
Net Asset Value per share (NAVPS)           Tk. 97.91           Tk. 91.01 
Net Operating Cash Flow Per Share           Tk. 13.64           Tk. 11.69 
 (NOCFPS) 
 

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: [phone], Ext.20080

S M Rabbur Reza, Chief Operating Officer

Tel: [phone], Ext.20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: [phone], Ext.20030

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: [phone] / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: [phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORGPGAWUUPWGCB

(END) Dow Jones Newswires

October 20, 2023 02:04 ET (06:04 GMT)